geoffrey modest medical blogs

  A recent study found that lenacapavir was a very effective med to prevent HIV infection in cisgender women (see   hiv pre-exp proph lenacapavir cisgender women NEJM2024  in dropbox, or DOI: 10.1056/NEJMoa2407001   Details : -- 5338 HIV-negative women in South Africa and Uganda were recruited into a phase 3, double-blind, randomized controlled trial of 3 groups to assess pre-exposure prophylaxis against HIV (PrEP):     -- subcutaneous lenacapavir 927mg every 26 weeks (with a window of up to 7 days) plus placebo tablets for F/TAF and F/TDF     -- daily oral F/TAF (emtricitabine-tenofovir alafenamide) plus placebo injections     -- daily oral F/TDF (emtricitabine-tenofovir disoproxil fumarate) plus placebo injections, serving as an active control -- the background in these countries: at least 3.5 adolescent girls and young women per 100 person-years developed incident HIV infections if not using PrEP -- the participants in ...

  Here is email form Albert Liu (forwarded with his permission), who was involved in the study, with link to FDA application for CAB approval and comment (not available to review) that study in a small trial of cis-gender women at high risk in Africa had dramatic protection from (89%) with CAB over TDF/FTC!!!   geoff   --------   Hi Geoff,   Thanks for your post about cabotegravir for PrEP! (we were one of the sites conducting the HPTN 083 trial)   I did want to let you know that a sister trial HPTN 084 was recently stopped early with similar findings of superiority of CAB over TDF/FTC in cisgender women in Africa:   https://www.nih.gov/news-events/news-releases/nih-study-finds-long-acting-injectable-drug-prevents-hiv-acquisition-cisgender-women   https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women ...

  A recent study found that cabotegravir (CAB) was better than TDF-FTC (tenofovir disoproxil fumarate/emtricitabine, or truvada, which is available as a generic) for preexposure prophylaxis (PrEP) against HIV (see  hiv pre-exp proph cabotegravir nejm2021  in dropbox, or DOI: 10.1056/NEJMoa2101016)    Details:  -- randomized, double-blind, noninferiority trial compared long-acting injectable CAB 600 mg given intramuscularly every eight weeks with daily oral TDF/FTC for the prevention of HIV infection in at-risk MSM and transgender women who have sex with men  -- multicenter trial in the United States (37%), Latin America (Argentina 7%/Brazil 17%/Peru 18%), Asia (Thailand 12%/Vietnam 4%), and Africa (3 %)  -- 4566 participants were randomized, including 570 (13%) transgender women  -- median age 26; in the US component, 845 (50%) were Black (ie, it was a racially diverse population)  -- all had negative HIV viral load within 14 days b...